---
layout: default
title: Bevacizumab
parent: Model Prediction Only (L5)
nav_order: 110
evidence_level: L5
indication_count: 10
---

# Bevacizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Bevacizumab: From Solid Tumor Therapy to Epiglottis Neoplasm

## One-Sentence Summary

Bevacizumab is an anti-VEGF-A monoclonal antibody, generally used to treat advanced solid tumors.
The TxGNN model predicts it may be effective for **epiglottis neoplasm**, but the prediction is model-derived only, with **0 clinical trials** and **0 publications** retrieved for this indication.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not listed in the source data (generally used in advanced solid tumors) |
| Predicted New Indication | Epiglottis neoplasm |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 13 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the source record. From general pharmacology, bevacizumab binds VEGF-A and blocks its signaling, which reduces the growth of new tumor blood vessels.

Head and neck tumors, including those of the epiglottis, are often highly vascularized, so blocking angiogenesis is biologically plausible. However, this is a generic argument. No study specific to epiglottis neoplasm was found, and the similarity to the original indication has not been assessed.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2520737 | BAMBEVI | Not listed | Not listed |
| 2522829 | AYBINTIO | Not listed | Not listed |
| 2522837 | AYBINTIO | Not listed | Not listed |
| 2489430 | ZIRABEV | Not listed | Not listed |
| 2520729 | BAMBEVI | Not listed | Not listed |

The record shows 13 licences in total, and only these 5 are listed here.

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-VEGF monoclonal antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction score is high, but there are no trials or publications for epiglottis neoplasm, so the evidence is at L5 (model prediction only). Safety data is also missing.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A dedicated evidence review for epiglottis neoplasm, including head and neck cancer trials of bevacizumab
- Original indication, dosage form and indication text for each licence, and confirmation of the regulatory source (the pack's input list names TFDA, while the market data is described as Health Canada)
- Consideration of the other predicted candidates. Cystic neoplasm (rank 7) has the most trial evidence (L3) but only indirect support, and cervical neuroblastoma (rank 6) is flagged as a research question.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

